Efficacy News and Research

RSS

BioLineRx second quarter net loss decreases to NIS 16.4 million

BioLineRx Ltd., a biopharmaceutical development company, today reported its results for the second quarter ending June 30, 2011.

23 Aug 2011

Helsinn begins enrollment in anamorelin Phase III trial for NSCLC-associated anorexia/cachexia

Helsinn, a Swiss-based pharmaceutical company, announced today that its US subsidiary, Helsinn Therapeutics, has enrolled the first patient in the company's pivotal Phase III clinical program of anamorelin HCl for the treatment of anorexia/cachexia in patients with advanced non-small cell lung cancer.

23 Aug 2011

Spinifex secures AU$6.25 million in expanded Series B funding

Spinifex Pharmaceuticals, an Australian pain drug development company, today announced it has secured a further AU$6.25 million of venture capital investment from GBS Venture Partners Limited, Brandon Capital Partners Pty Limited, Uniseed Management Pty Limited and UniQuest Pty Limited to fund the development of its pain management drug, EMA401.

23 Aug 2011

OICR President announces $12.6M in funding for High Impact Clinical Trials Program

Dr. Tom Hudson, President and Scientific Director of the Ontario Institute for Cancer Research (OICR), today announced $12.6 million in funding over four years for OICR's High Impact Clinical Trials (HICT) Program.

23 Aug 2011

Symphogen initiates Sym004 Phase 2 trial in squamous cell carcinoma of head and neck cancer

Symphogen A/S today announced the initiation of a Phase 2 clinical trial to investigate the safety and efficacy of Sym004 in patients who have failed anti-EGFR monoclonal antibody (mAb)-based therapy, with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

23 Aug 2011

IsoRay Cs-131 mesh brachytherapy with da Vinci Robot for lung cancer treatment gains momentum

IsoRay, Inc. said today that a growing number of hospitals and medical treatment centers are adopting its proprietary mesh Cesium-131 (Cs-131) brachytherapy seeds (internal radiation therapy) for use in conjunction with the da Vinci® Surgical System to treat early stage lung cancer patients. One of the most recent adopters is Georgia's Archbold Memorial Hospital.

23 Aug 2011

First computerized genome-scale model of cancer cell metabolism

Scientists are constantly on the hunt for treatments that can selectively target cancer cells, leaving other cells in our bodies unharmed.

22 Aug 2011

AHF: Gilead's campaign for FDA approval of Truvada leads to black marketing in Florida

Today AIDS Healthcare Foundation (AHF) decried the fact that the recent campaign by Gilead Sciences Inc. to obtain approval by the U.S. Food & Drug Administration for Truvada as PrEP (pre-exposure prophylaxis) has led to a "black market" for the drug in Florida.

20 Aug 2011

VOA News examines new drug compound that shows broad-based efficacy in lab tests

VOA News looks at a new drug compound developed by researchers at the Massachusetts Institute of Technology (MIT) that they say has so far "killed every virus it's been tested on in the laboratory." "The drug - known by the acronym DRACO - works by chemically targeting viral-infected cells and prompting them to self-destruct, eliminating the disease in the process," VOA writes.

20 Aug 2011

Only 15 U.S. pharmaceutical ads adhere to FDA Prescription Drug Advertising Guidelines

A study led by Mount Sinai School of Medicine researchers of 192 pharmaceutical advertisements in biomedical journals found that only 18 percent were compliant with Food and Drug Administration (FDA) guidelines, and over half failed to quantify serious risks including death.

19 Aug 2011

New Therapy Grants Program supports innovative approach to treat epilepsy

The Epilepsy Therapy Project (ETP) and the Epilepsy Foundation (EF) announced today a New Therapy Grant to potentially help those with treatment resistant epilepsy.

19 Aug 2011

H1N1 vaccine safe, effective for hemodialysis and kidney transplant patients

When the influenza A (H1N1) virus swept around the world in spring 2009, infection was presumed to be more common in immunosuppressed patients, such as those who have had a kidney transplant. Later that year, the International Societies of Transplantation recommended that transplant recipients receive at least one dose of the H1N1 vaccine, although there was no information on the efficacy of the vaccine in that population.

19 Aug 2011

Amgen to present data from several Prolia studies at ASBMR 2011 meeting

Amgen today announced that it will present data from several Prolia (denosumab) studies, including eight year efficacy and safety data from a Phase 2 extension study in women with postmenopausal osteoporosis with low bone mineral density (BMD), at the 2011 American Society for Bone and Mineral Research (ASBMR) Annual Meeting in San Diego, Calif. from Sept. 16-20, 2011.

19 Aug 2011

Gene Security Network announces commercial launch of non-invasive prenatal test

Gene Security Network Inc. (GSN) today announced the commercial launch of its first non-invasive prenatal test powered by the company's proprietary bioinformatics technology, Parental Support™.

18 Aug 2011

NPS submits NDA CMC section to FDA for GATTEX

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing orphan therapeutics for rare gastrointestinal and endocrine disorders, today announced that it has submitted the chemistry, manufacturing and controls (CMC) section of its new drug application (NDA) for GATTEX® (teduglutide) to the U.S. Food and Drug Administration (FDA).

18 Aug 2011

NCRM at Case Western Reserve to host stem cell conference in Cleveland

The National Center for Regenerative Medicine (NCRM) at Case Western Reserve University is proud to present "MSC 2011: Innovations in Cell-Based Regenerative Therapies," a three-day forum to highlight transformative breakthroughs in the area of adult stem cell medicine with a focus on how this research is being applied in patient care settings through innovative clinical trials.

18 Aug 2011

CEL-SCI receives Chinese patent for Multikine cancer drug

CEL-SCI Corporation today announced that the Chinese patent office has issued a key patent covering CEL-SCI's investigational cancer drug, Multikine.

18 Aug 2011

Emergent commences TRU-016 Phase 1b/2 combination trial in relapsed indolent NHL

Emergent BioSolutions Inc. today announced the initiation of a Phase 1b/2 study (16011) of TRU-016 in combination with rituximab and bendamustine for patients with relapsed indolent non-Hodgkin's B-cell lymphomas, including follicular lymphoma, small lymphocytic lymphoma and marginal zone lymphoma.

17 Aug 2011

Neovasc completes previously announced non-brokered private placement

Neovasc Inc. today announced that it has completed a previously announced non-brokered private placement of 4,720,500 equity units at the price of $1.00 per unit for aggregate gross proceeds of approximately $4,720,500.

17 Aug 2011

Patient recruitment complete in Kuros' KUR-023 dural sealant European clinical trial

Kuros Biosurgery AG, a biotechnology company focused on the development of novel biomaterials and bioactive-biomaterial combination products for trauma, wound and spinal indications, announced today that it has completed patient recruitment in a clinical trial investigating the safety and efficacy of KUR-023, its novel dural sealant product candidate.

17 Aug 2011

Efficacy News and Research

BioLineRx second quarter net loss decreases to NIS 16.4 million

Helsinn begins enrollment in anamorelin Phase III trial for NSCLC-associated anorexia/cachexia

Spinifex secures AU$6.25 million in expanded Series B funding

OICR President announces $12.6M in funding for High Impact Clinical Trials Program

Symphogen initiates Sym004 Phase 2 trial in squamous cell carcinoma of head and neck cancer

IsoRay Cs-131 mesh brachytherapy with da Vinci Robot for lung cancer treatment gains momentum

First computerized genome-scale model of cancer cell metabolism

AHF: Gilead's campaign for FDA approval of Truvada leads to black marketing in Florida

VOA News examines new drug compound that shows broad-based efficacy in lab tests

Only 15 U.S. pharmaceutical ads adhere to FDA Prescription Drug Advertising Guidelines

New Therapy Grants Program supports innovative approach to treat epilepsy

H1N1 vaccine safe, effective for hemodialysis and kidney transplant patients

Amgen to present data from several Prolia studies at ASBMR 2011 meeting

Gene Security Network announces commercial launch of non-invasive prenatal test

NPS submits NDA CMC section to FDA for GATTEX

NCRM at Case Western Reserve to host stem cell conference in Cleveland

CEL-SCI receives Chinese patent for Multikine cancer drug

Emergent commences TRU-016 Phase 1b/2 combination trial in relapsed indolent NHL

Neovasc completes previously announced non-brokered private placement

Patient recruitment complete in Kuros' KUR-023 dural sealant European clinical trial

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News